Wells Fargo & Company MN grew its position in Henry Schein, Inc. (NASDAQ:HSIC) by 70.9% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,064,399 shares of the company’s stock after purchasing an additional 441,561 shares during the period. Wells Fargo & Company MN owned about 0.71% of Henry Schein worth $74,401,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in HSIC. CSat Investment Advisory L.P. raised its holdings in shares of Henry Schein by 115.6% in the first quarter. CSat Investment Advisory L.P. now owns 552 shares of the company’s stock valued at $33,000 after purchasing an additional 296 shares during the last quarter. Parallel Advisors LLC raised its holdings in shares of Henry Schein by 67.4% in the first quarter. Parallel Advisors LLC now owns 586 shares of the company’s stock valued at $35,000 after purchasing an additional 236 shares during the last quarter. Cullen Frost Bankers Inc. purchased a new stake in shares of Henry Schein in the second quarter valued at about $36,000. Ibex Wealth Advisors purchased a new stake in shares of Henry Schein in the second quarter valued at about $40,000. Finally, Rational Advisors LLC raised its holdings in shares of Henry Schein by 1,012.3% in the first quarter. Rational Advisors LLC now owns 723 shares of the company’s stock valued at $43,000 after purchasing an additional 658 shares during the last quarter.

Shares of NASDAQ:HSIC opened at $61.35 on Friday. The company has a quick ratio of 0.95, a current ratio of 1.70 and a debt-to-equity ratio of 0.33. The firm has a market capitalization of $8.96 billion, a PE ratio of 14.85, a P/E/G ratio of 2.37 and a beta of 0.84. Henry Schein, Inc. has a twelve month low of $56.58 and a twelve month high of $72.81. The company has a 50-day moving average price of $64.91 and a two-hundred day moving average price of $64.43.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, August 6th. The company reported $0.84 earnings per share for the quarter, topping analysts’ consensus estimates of $0.83 by $0.01. The firm had revenue of $2.45 billion during the quarter, compared to analyst estimates of $2.48 billion. Henry Schein had a net margin of 4.18% and a return on equity of 16.67%. The company’s quarterly revenue was up 5.7% on a year-over-year basis. During the same quarter last year, the business earned $1.04 earnings per share. Analysts anticipate that Henry Schein, Inc. will post 3.46 earnings per share for the current fiscal year.

In other Henry Schein news, Vice Chairman James P. Breslawski sold 6,856 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $60.17, for a total transaction of $412,525.52. Following the completion of the transaction, the insider now owns 249,046 shares in the company, valued at $14,985,097.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Walter Siegel sold 4,068 shares of the firm’s stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $71.29, for a total transaction of $290,007.72. Following the completion of the transaction, the vice president now owns 48,703 shares of the company’s stock, valued at $3,472,036.87. The disclosure for this sale can be found here. Insiders have sold 56,524 shares of company stock valued at $3,984,949 in the last quarter. Company insiders own 1.06% of the company’s stock.

HSIC has been the subject of several analyst reports. Svb Leerink reiterated a “market perform” rating and issued a $70.00 target price (down previously from $75.00) on shares of Henry Schein in a report on Wednesday, May 15th. Wolfe Research assumed coverage on shares of Henry Schein in a report on Thursday, May 30th. They set an “underperform” rating for the company. Leerink Swann downgraded shares of Henry Schein from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $75.00 to $70.00 in a report on Wednesday, May 15th. They noted that the move was a valuation call. Barrington Research restated a “buy” rating and set a $75.00 price objective on shares of Henry Schein in a report on Wednesday, August 7th. Finally, Craig Hallum restated a “buy” rating and set a $77.00 price objective (up previously from $72.00) on shares of Henry Schein in a report on Wednesday, May 8th. Seven research analysts have rated the stock with a sell rating, nine have issued a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $73.64.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.

Featured Article: Gross Domestic Product (GDP)

Institutional Ownership by Quarter for Henry Schein (NASDAQ:HSIC)

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with MarketBeat.com's FREE daily email newsletter.